Zobrazeno 1 - 10 of 33 pro vyhledávání: '"Ashwin, Shahir"'
1
Akademický článek
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study
Autor: Matthew P. Goetz, Irfan Cicin, Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen R. D. Johnston, Miguel Martin, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S. Rugo, Joyce O’Shaughnessy
Publikováno v: npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to p
Externí odkaz: https://doaj.org/article/1378a75d34cd4a89ad1255e30c08bb59
Zobrazit plný text záznamu
2
Akademický článek
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
Autor: Shani Paluch-Shimon, Patrick Neven, Jens Huober, Irfan Cicin, Matthew P. Goetz, Chikako Shimizu, Chiun-Sheng Huang, Hans Joachim Lueck, Jane Beith, Eriko Tokunaga, Jessica Reyes Contreras, Rosane Oliveira de Sant’Ana, Ran Wei, Ashwin Shahir, Sarah C. Nabinger, Tammy Forrester, Stephen R. D. Johnston, Nadia Harbeck
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), node-positive, and high-risk ear
Externí odkaz: https://doaj.org/article/9dbf86693a4a460dbf6601907c6ba0ed
Zobrazit plný text záznamu
3
Akademický článek
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
Autor: Leo Mascarenhas, Chitose Ogawa, Theodore W. Laetsch, Brenda J. Weigel, Michael W. Bishop, Julie Krystal, Scott C. Borinstein, Emily K. Slotkin, Jodi A. Muscal, Pooja Hingorani, Donna E. Levy, Gary Mo, Ashwin Shahir, Jennifer Wright, Steven G. DuBois
Publikováno v: Cancer Medicine, Vol 10, Iss 3, Pp 843-856 (2021)
Abstract Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recomm
Externí odkaz: https://doaj.org/article/728f5f60eab94b5f8c5a384248851207
Zobrazit plný text záznamu
4
Akademický článek
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
Autor: Victor M. Villalobos, Gary Mo, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun Singh, Brian A. Van Tine, Rhian McNaughton, Rodney L. Decker, Wei Zhang, Ashwin Shahir, Damien M. Cronier
Publikováno v: Cancer Medicine, Vol 9, Iss 3, Pp 882-893 (2020)
Abstract Background Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxo
Externí odkaz: https://doaj.org/article/ea5713e478994fba9c19d01324de61f2
Zobrazit plný text záznamu
7
Akademický článek
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
Autor: William P. McGuire, Richard T. Penson, Martin Gore, Antonio Casado Herraez, Patrick Peterson, Ashwin Shahir, Robert Ilaria
Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes. Thi
Externí odkaz: https://doaj.org/article/aec05d6fed2e4b8d95e91fcd8dfd28b0
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje